About Myopia

Myopia is a serious and growing problem

By 2050, an estimated 1 in 2 people (5 billion) will have myopia1
Almost 20% of them (1 billion) will have high myopia1
Myopia will be the world’s leading cause of blindness1

The most common ocular disorder in the world

Our eyesight is vital to learning and navigating the world around us, and to leading productive lives. As humanity spends more time indoors, myopia (short-sightedness) is now the most common eye disorder globally, and its incidence is escalating rapidly. 

Myopia gets progressively worse as life goes on

Myopia is a condition where people can see close objects clearly, but further away objects appear blurred. If not well-controlled, myopia worsens over time. High myopia is then associated with significantly increased risks of retinal disease, glaucoma and cataracts.

Global impact on humanity

By 2050, the predicted explosion of this degenerative condition will affect 1 in 2 people, or 5 billion globally. Almost 1 billion will have high myopia, becoming the world’s leading cause of permanent blindness¹.
Infographic Source: International Myopia Institute, myopiainstitute.org/myopia/

There is no perfect treatment for childhood myopia

Childhood myopia progresses over time unless well-controlled. Specialised contact lenses, atropine eye drops and novel spectacle designs have all been shown to slow progression. However, each of these interventions has its complexities, especially as contact lenses and eye drops can be difficult for young children to remain compliant with, which can in turn reduce treatment uptake and efficacy.

A powerful new addition to existing therapies

Eyerising International’s commitment to leading the fight against childhood myopia led to the development of our patented Eyerising Myopia Management Device Repeated Low-Level Red-Light (RLRL) therapy, a highly effective and child-friendly way to treat myopia.

The device is clinically proven to slow the progression of child myopia by up to 87.7%7. It is designed to be used at home with 3 minutes of treatment, twice a day, 5 days per week and a minimum of 4 hours between sessions.
See the device

References

1. Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, Wong TY, Naduvilath TJ, Resnikoff S. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050.
2. Ophthalmology. 2016 May;123(5):1036-42. doi: 10.1016/j.ophtha.2016.01.006. Epub 2016 Feb 11. PMID: 26875007.
Mehta, N. and Wen, A. (2019) Myopia: A global epidemic, Retina Today. Available at: https://retinatoday.com/articles/2019-sept/myopia-a-global-epidemic (Accessed: 12 March 2024). 
3. Ruiz-Pomeda A, Pérez-Sánchez B, Valls I, et al. MiSight Assessment Study Spain (MASS). A 2-year randomized clinical trial. Graefes Arch Clin Exp Ophthalmol. 2018;256(5):1011-1021.
4. Eyenovia enrolls first patient in phase III CHAPERONE Study for progressive myopia [news release]. New York: Globe Newswire; June 4, 2019. https://www.globenewswire.com/news-release/2019/06/04/1863931/0/en/Eyenovia-Enrolls-First-Patient-in-Phase-III-CHAPERONE-Study-for-Progressive-Myopia.html. Accessed June 25, 2019.
5. Lam CSY, Tang WC, Tse DY, et al. Defocus incorporated multiple segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial [published online ahead of print May 29, 2019]. Br J Ophthalmol. doi: 10.1136/bjophthalmol-2018-313739. Singapore National Eye Centre, Singapore Eye Research Institute, and Johnson & Johnson Vision set sights on halting global myopia epidemic [news release].
6. Singapore: PRNewswire; November 12, 2018. https://www.prnewswire.com/news-releases/singapore-national-eye-centre-singapore-eye-research-institute-and-johnson–johnson-vision-set-sights-on-halting-global-myopia-epidemic-300747895.html. Accessed June 25, 2019.
7. Jiang, Yu, et al. “Effect of repeated low-level red-light therapy for myopia control in children: a multicenter randomized controlled trial.” Ophthalmology 129.5 (2022): 509-519.

navigation

We acknowledge the Wurundjeri Woi Wurrung people as the Traditional Owners of the land on which our offices are situated, and pay our respects to their Elders, past, present, and emerging.